ClinicalTrials.gg
RecruitingNCT07179055Updated Sep 17, 2025

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

A Phase 2 interventional study of VSJ-110 and Placebo in Dry Eye, sponsored by Vanda Pharmaceuticals. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Planned enrollment
127th of 473
160 · median 60
Started
2025
with 22 others
Phase 2
97 of 544
5 open now
Primary completion
2026-09
later than 15 of 62 live
Registered
500th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 127th largest by planned enrollment of the 473 interventional ones that give a count, is one of 23 that started in 2025, is one of 97 in phase 2, reaches primary completion later than 15 of the 62 other live ones, and was the 500th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age of either gender and any race.
  • Provide written and sign the HIPAA form.
  • Be willing and able to follow all instructions and attend all study visits.

Exclusion criteria

Exclusion Criteria:

  • Use of any of the disallowed medications during the and study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    VSJ-110 Solution

    Drug: VSJ-110

  • Placebo comparator
    Placebo Solution

    Drug: Placebo

Interventions

  • ophthalmic solution

  • DrugPlacebo

    ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Corneal Staining

    Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.

    Time frame: Measured over an 8-week treatment period

Secondary outcomes

  1. Schirmer's Tear Test

    Schirmer tear test strips are used to measure ocular fluid.

    Time frame: Measured over an 8-week treatment period

  2. Eye Dryness Score (EDS) of the Visual Analogue Scale (VAS)

    EDS is reported by the subject using a 100-point scale (0=no discomfort and 100=maximum discomfort).

    Time frame: Measured over an 8-week treatment period

07

Study locations

2 of 5 sites recruiting
  • Vanda Investigational Site
    Newport Beach, California 92663, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Andover, Massachusetts 01810, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Shelby, North Carolina 28150, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Memphis, Tennessee 38119, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Lynchburg, Virginia 24502, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Sep 2026, 11 months later.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 11 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartEst.
Oct 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07179055
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Oct 2025 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Vanda Pharmaceuticals
Contact
clinicaltrials@vandapharma.com
202-734-3400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VSJ-110

Start the discussion